Cargando…

Real-world Experience of Approved Chimeric Antigen Receptor T-cell Therapies Compared to Clinical Trials Data

Detalles Bibliográficos
Autores principales:	Lambert, Jérôme, Di Blasi, Roberta, Rabian, Florence, Dourthe, Marie-Emilie, Baruchel, André, Thiéblemont, Catherine, Boissel, Nicolas, Levy, Vincent, Picat, Marie-Quitterie, Chevret, Sylvie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228472/ https://www.ncbi.nlm.nih.gov/pubmed/37260917 http://dx.doi.org/10.1097/HS9.0000000000000873

Ejemplares similares

The use of ICU resources in CAR-T cell recipients: a hospital-wide study
por: Valade, Sandrine, et al.
Publicado: (2022)

Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis
por: Cerrano, Marco, et al.
Publicado: (2023)

Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL
por: Dourthe, Marie Emilie, et al.
Publicado: (2023)

Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications
por: Fodil, Sofiane, et al.
Publicado: (2022)

The oncogenetic landscape and clinical impact of BCL11B alterations in adult and pediatric T-cell acute lymphoblastic leukemia
por: Dourthe, Marie Emilie, et al.
Publicado: (2023)

Chimeric Antigen Receptor-T Cell Therapy: Practical Considerations for Implementation in Europe
por: Buechner, Jochen, et al.
Publicado: (2018)

P321: TNF-MEDIATED CELL DEATH: AN ACTIONABLE TARGET FOR IMMUNOTHERAPY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Dourthe, Marie-Emilie, et al.
Publicado: (2023)

Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma
por: Liévin, Raphaël, et al.
Publicado: (2022)

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
por: Boissel, Laurent, et al.
Publicado: (2013)

Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival
por: Canet, Emmanuel, et al.
Publicado: (2013)

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells
por: Darowski, Diana, et al.
Publicado: (2019)

Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study
por: Zerbit, Jeremie, et al.
Publicado: (2020)

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
por: Le, Robert Q., et al.
Publicado: (2018)

Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL
por: Smith, Charlotte, et al.
Publicado: (2023)

TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2
por: Balducci, Estelle, et al.
Publicado: (2023)

Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital
por: Vallet, Nicolas, et al.
Publicado: (2021)

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
por: Dufort, Sandrine, et al.
Publicado: (2011)

Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients
por: Picat, Marie-Quitterie, et al.
Publicado: (2017)

S106: METABOLIC PLASTICITY REVEALS A TARGETABLE VULNERABILITY IN LEUKEMIA
por: Andrieu, Guillaume, et al.
Publicado: (2023)

Design of chimeric antigen receptors with integrated controllable transient functions
por: Juillerat, Alexandre, et al.
Publicado: (2016)

T-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adults
por: Picat, Marie-Quitterie, et al.
Publicado: (2014)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins
por: Steimlé, Thomas, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?
por: Buechner, Jochen, et al.
Publicado: (2022)

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma
por: Cuffel, Alexis, et al.
Publicado: (2022)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Enriching single-arm clinical trials with external controls: possibilities and pitfalls
por: Lambert, Jérôme, et al.
Publicado: (2022)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study
por: Picat, Marie-Quitterie, et al.
Publicado: (2013)

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia
por: Rabian, Florence, et al.
Publicado: (2019)

Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
por: Fanciulli, Giuseppe, et al.
Publicado: (2022)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cells: The Future Is Now
por: Mchayleh, Wassim, et al.
Publicado: (2019)

A TCR-based Chimeric Antigen Receptor
por: Walseng, Even, et al.
Publicado: (2017)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kngt40ckq3j5s201j04a1hleua